EVALUATION OF PROHYPERTENSIVE EFFECT OF MELOXICAM ON THE BLOOD PRESSURE INDICATORS
https://doi.org/10.20514/2226-6704-2019-9-1-60-63
Abstract
The goal is to evaluate the influence of meloxicam on the level of blood pressure among patients suffering from hypertension, as well as among patients without diseases of the cardiovascular system, in relation to its pro-hypertensive effect.
Materials and methods. The retrospective research involved 60 patients who regularly taked meloxicam in a dose of 7.5 mg / day. There were patients who didn’t have a cardiovascular pathology in the first group. The second group consisted of patients with hypertension, taking antihypertensive drugs. Retrospectively, the level of blood pressure, measured by the Korotkov’s method, was analyzed by medical histories, before and after 3 months of taking meloxicam in both groups. The total cardiovascular risk was calculated on a SCORE scale.
Results. It was determinated that long-term medication of meloxicam led to an increase of blood pressure indicators, both in patients without established diseases of the cardiovascular system, and in patients with the hypertension and an average total cardiovascular risk, who are regularly taking antihypertensive pills to achieve target blood pressure.
About the Authors
R. V. Nikiforov
Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Department of polyclinic therapy
Voronezh
V. I. Shevcova
Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Department of polyclinic therapy
Voronezh
A. A. Zuykova
Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Department of polyclinic therapy
Voronezh
References
1. Karateev A.E. Celecoxib, Еtoricoxib, Мeloxicam, and Nimesulide: comparison of their merits and demerits. NeuroNEWS. 2015; 4(68): 18-24 [In Russian].
2. Rodionov A.V. Non-steroid antipyretic preparations and arterial hypertension: actual character of the problem and the strategy of conducting patients. Attending doctor. 2013; 2: 25-31 [In Russian].
3. Balabanova R.M. Algorithm of using of nonsteroidal antiinflammatory drugs in the therapeutic practice. Russian Medical Journal. 2013; 5: 265 — 269 [In Russian].
4. Dalal D., Dubreuil M., Peloquin C. et al. Meloxicam and risk of myocardial infarction: a population-based nested case-control study. Rheumatology International. 2017;3 7(12): 2017-2078.
5. Zheng Liuying, Du Xinping. Non-steroidal anti-inflammatory drugs and hypertension. Cell Biochemistry & Biophysics. 2014; 69(2): 209-211.
6. Chazova I.E. Oshchepkova E.V. Zhernakova Y.V. Diagnosis and treatment of arterial hypertension. Clinical guidelines. Russian Cardiology Bulletin. 2015; 10(1): 3-30 [In Russian].
7. Zolotovskaya I.A., Davydkin I.L., Borovkova N.Y. Renal-associated escape effect of antihypertensive therapy in hypertensive patients receiving nonsteroidal anti-inflammatory drugs («PANDA» trial). «Arterial’naya gipertenziya» («Arterial hypertension»). 2017; 23(6): 517-528 [In Russian].
8. Akarachkova E.S., Gromova O.A., Kotova O.V. Selection of modern safe and effective NSAID in patients with concomitant (comorbid) diseases. Farmateka. 2016; 7(320): 43-48 [In Russian].
9. Eliseev M.S., Barskova V.G. Meloxicam: what do we know about cardiovascular safety. Modern rheumatology. 2010; 4(1): 79-83 [In Russian].
10. Lasebnik L.B., Kotsubinskaya O.B., Konev Y.V., Drosdov V.N. Effect of nonsteroidal anti-inflammatory drugs and tramal on blood pressure level during osteoarthritis treatment in patients with hypertension. Rheumatology Science and Practice. 2004; 42(1): 28-33 [In Russian].
11. Karateev A.E., Nasonov E.L., Yahno N.N. ets. Clinical recommendations “The rational using of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice.” Modern rheumatology. 2015; 1: 4-23 [In Russian].
12. Angiolillo D.J., Weisman S.M. Clinical Pharmacology and Cardiovascular Safety of Naproxen. American Journal of Cardiovascular Drugs. 2017;17(2):97–107.
Review
For citations:
Nikiforov R.V., Shevcova V.I., Zuykova A.A. EVALUATION OF PROHYPERTENSIVE EFFECT OF MELOXICAM ON THE BLOOD PRESSURE INDICATORS. The Russian Archives of Internal Medicine. 2019;9(1):60-63. https://doi.org/10.20514/2226-6704-2019-9-1-60-63
Views:
17868
Email this article 